Suppr超能文献

针对ClbP特异性抑制剂的筛选方法。

Screening method toward ClbP-specific inhibitors.

作者信息

Zhou Tao, Ando Takayuki, Kudo Akihiro, Sato Michio, Miyoshi Noriyuki, Mutoh Michihiro, Ishikawa Hideki, Wakabayashi Keiji, Watanabe Kenji

机构信息

Adenoprevent Co., Ltd., Shizuoka, 422-8526, Japan.

Department of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, 422-8526, Japan.

出版信息

Genes Environ. 2023 Feb 16;45(1):8. doi: 10.1186/s41021-023-00264-7.

Abstract

BACKGROUND

Colibactin is a genotoxin produced by Escherichia coli and other Enterobacteriaceae that is believed to increase the risk of colorectal cancer (CRC) of their symbiosis hosts, including human. A peptidase ClbP is the key enzyme for activation of colibactin. Inhibition of ClbP is considered to impede maturation of precolibactin into genotoxic colibactin. Therefore, ClbP-specific inhibitors could potentially prevent the onset of CRC, one of the leading causes of cancer-related deaths in the world. This study intends to establish an efficient screening system for identifying inhibitors that are specific to ClbP.

METHODS

Two types of assays were applied in the screening procedure: a probe assay and an LC-MS assay. For the probe assay, we employed the synthesized probe which we described in our previous report. This probe can be hydrolyzed efficiently by ClbP to release a fluorophore. Hence it was applied here for detection of inhibition of ClbP. For the LC-MS assay, formation of the byproduct of precolibactin maturation process, N-myristoyl-D-asparagine, was quantified using a liquid chromatography-mass spectrometry (LC-MS) technique. The probe assay can be performed much faster, while the LC-MS assay is more accurate. Therefore, our method employed the two assays in sequence to screen a large number of compounds for inhibition of ClbP.

RESULTS

A library of 67,965 standard compounds was evaluated by the screening method established in the current study, and one compound was found to show a moderate inhibitory activity against ClbP.

CONCLUSION

A simple screening method for ClbP-specific inhibitors was established. It was proven to be reliable and is believed to be useful in developing potential prophylactic agents for CRC.

摘要

背景

大肠杆菌素是由大肠杆菌和其他肠杆菌科细菌产生的一种基因毒素,据信会增加其共生宿主(包括人类)患结直肠癌(CRC)的风险。肽酶ClbP是激活大肠杆菌素的关键酶。抑制ClbP被认为会阻碍前体大肠杆菌素成熟为具有基因毒性的大肠杆菌素。因此,ClbP特异性抑制剂有可能预防CRC的发生,CRC是全球癌症相关死亡的主要原因之一。本研究旨在建立一种高效的筛选系统,以鉴定对ClbP具有特异性的抑制剂。

方法

在筛选过程中应用了两种类型的检测方法:探针检测法和液相色谱-质谱(LC-MS)检测法。对于探针检测法,我们使用了我们之前报告中描述的合成探针。该探针可被ClbP有效水解以释放荧光团。因此,它在此处用于检测ClbP的抑制作用。对于LC-MS检测法,使用液相色谱-质谱(LC-MS)技术对前体大肠杆菌素成熟过程的副产物N-肉豆蔻酰-D-天冬酰胺的形成进行定量。探针检测法可以更快地进行,而LC-MS检测法更准确。因此,我们的方法依次使用这两种检测方法来筛选大量抑制ClbP的化合物。

结果

通过本研究建立的筛选方法对一个包含67,965种标准化合物的文库进行了评估,发现一种化合物对ClbP表现出中等抑制活性。

结论

建立了一种针对ClbP特异性抑制剂的简单筛选方法。已证明该方法可靠,并且有望用于开发潜在的CRC预防药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8d0/9933310/abc77d299430/41021_2023_264_Fig1_HTML.jpg

相似文献

1
Screening method toward ClbP-specific inhibitors.
Genes Environ. 2023 Feb 16;45(1):8. doi: 10.1186/s41021-023-00264-7.
2
A small molecule inhibitor prevents gut bacterial genotoxin production.
Nat Chem Biol. 2023 Feb;19(2):159-167. doi: 10.1038/s41589-022-01147-8. Epub 2022 Oct 17.
3
In Vitro Characterization of the Colibactin-Activating Peptidase ClbP Enables Development of a Fluorogenic Activity Probe.
ACS Chem Biol. 2019 Jun 21;14(6):1097-1101. doi: 10.1021/acschembio.9b00069. Epub 2019 May 13.
5
Structural basis of colibactin activation by the ClbP peptidase.
Nat Chem Biol. 2023 Feb;19(2):151-158. doi: 10.1038/s41589-022-01142-z. Epub 2022 Oct 17.
6
Analysis of structure-function relationships in the colibactin-maturating enzyme ClbP.
J Mol Biol. 2012 Dec 7;424(3-4):203-14. doi: 10.1016/j.jmb.2012.09.017. Epub 2012 Oct 2.
7
Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria.
Gut. 2016 Feb;65(2):278-85. doi: 10.1136/gutjnl-2014-307241. Epub 2015 Jan 14.
8
Activity-Based Probe for Screening of High-Colibactin Producers from Clinical Samples.
Org Lett. 2019 Jun 21;21(12):4490-4494. doi: 10.1021/acs.orglett.9b01345. Epub 2019 Jun 13.
9
The Colibactin Genotoxin Generates DNA Interstrand Cross-Links in Infected Cells.
mBio. 2018 Mar 20;9(2):e02393-17. doi: 10.1128/mBio.02393-17.
10
Synthesis and reactivity of precolibactin 886.
Nat Chem. 2019 Oct;11(10):890-898. doi: 10.1038/s41557-019-0338-2. Epub 2019 Sep 23.

本文引用的文献

1
Biosynthesis and bioactivities of microbial genotoxin colibactins.
Nat Prod Rep. 2022 May 26;39(5):991-1014. doi: 10.1039/d1np00050k.
2
Mother-to-infant transmission of the carcinogenic colibactin-producing bacteria.
BMC Microbiol. 2021 Aug 24;21(1):235. doi: 10.1186/s12866-021-02292-1.
3
Isolation of New Colibactin Metabolites from Wild-Type and Trapping of a Mature Colibactin Derivative.
J Am Chem Soc. 2021 Apr 14;143(14):5526-5533. doi: 10.1021/jacs.1c01495. Epub 2021 Mar 31.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
Structure and bioactivity of colibactin.
Bioorg Med Chem Lett. 2020 Aug 1;30(15):127280. doi: 10.1016/j.bmcl.2020.127280. Epub 2020 May 23.
6
Structure elucidation of colibactin and its DNA cross-links.
Science. 2019 Sep 6;365(6457). doi: 10.1126/science.aax2685. Epub 2019 Aug 8.
7
Activity-Based Probe for Screening of High-Colibactin Producers from Clinical Samples.
Org Lett. 2019 Jun 21;21(12):4490-4494. doi: 10.1021/acs.orglett.9b01345. Epub 2019 Jun 13.
8
Cancer-associated fecal microbial markers in colorectal cancer detection.
Int J Cancer. 2017 Dec 15;141(12):2528-2536. doi: 10.1002/ijc.31011. Epub 2017 Sep 6.
9
Convergent and Modular Synthesis of Candidate Precolibactins. Structural Revision of Precolibactin A.
J Am Chem Soc. 2016 Apr 27;138(16):5426-32. doi: 10.1021/jacs.6b02276. Epub 2016 Apr 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验